StockNews.AI
VEEV
StockNews.AI
202 days

More Than 200 Companies Advance Trial Management with Veeva CTMS

1. Over 200 companies, including top biopharmas, use Veeva CTMS for trials. 2. Veeva CTMS enhances collaboration by centralizing trial data and documents. 3. New advancements improve trial management for insourced and outsourced models. 4. Veeva's continued innovation aligns with evolving clinical regulations and needs. 5. Adoption of Veeva CTMS accelerates trial execution while ensuring compliance.

6m saved
Insight
Article

FAQ

Why Bullish?

Increased adoption of Veeva CTMS by leading firms suggests strong demand, potentially lifting VEEV's stock.

How important is it?

High relevance and adoption of Veeva's product directly relate to VEEV's market position.

Why Long Term?

As more biopharma companies integrate Veeva CTMS, VEEV could experience sustained growth.

Related Companies

VEEVINCYREGN
Biopharmas use leading CTMS for improved trial efficiency and collaboration , /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that more than 200 companies – including 17 of the top 20 biopharmas – use Veeva CTMS to execute faster, more efficient trials. As study complexity and data volumes increase, biopharmas and CROs are centralizing data and documents with Veeva CTMS to streamline processes and drive stakeholder collaboration. "Veeva CTMS is the central hub of our trials, allowing study metrics and documents to flow seamlessly across our ecosystem," said Bonne Adams, vice president of operations at Inhibrx. "Using clinical applications on a connected platform saves time and effort for our lean team and improves how we work with CRO partners." Whether biopharmas insource or outsource trials, clinical teams can use Veeva CTMS to proactively manage studies and quickly identify and address issues. With a flexible and scalable system, companies can accelerate trial execution and deliver high-quality data while maintaining compliance with global regulations like ICH E6(R2) and (R3). To help biopharmas adapt to trial operating model changes and keep up with evolving regulations, Veeva continues to deliver clinical innovations. New Veeva CTMS advancements include: CTMS transfer automates daily data transfers from CROs to sponsors for greater visibility Oversight issue tracking and management for faster resolution Enhancements to manage insourced, outsourced, and complex trials for speed and agility "Modern clinical trial management systems should scale easily and support both insourced and outsourced operating models," said Henry Galio, vice president of Veeva CTMS strategy. "To provide this flexibility, we're delivering new capabilities for Veeva CTMS through our three product releases per year, continuously advancing to help the industry work better together and accelerate execution." With the increased adoption of Veeva CTMS, more companies are simplifying trial operations and maintaining compliance regardless of operating model. Veeva CTMS is part of Veeva Clinical Platform, the most complete and highest-quality platform for faster and more efficient trials. Learn more about Veeva CTMS at SCOPE 2025 booth 916, Feb. 3-6 in Orlando. Additional InformationFor more on Veeva CTMS, visit: veeva.com/CTMS Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems About Veeva SystemsVeeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com. Veeva Forward-looking StatementsThis release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10- Q for the period ended October 31, 2024, which you can find here (a summary of risks which may impact our business can be found on pages 36 and 37), and in our subsequent SEC filings, which you can access at sec.gov. Contact: SOURCE Veeva Systems WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News